ArticleNagoya journal of medical science2025
Early introduction of intravenous oxycodone injection followed by quick titration to oral oxycodone in outpatient cancer pain treatment in opioid-naïve patients: "oxycodone bridge method".
Article in Nagoya journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological Mechanisms and Clinical Applications of Oxycodone in Cancer Pain Management: A Narrative Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following opioid therapy initiation in opioid-naïve outpatients, cancer-related pain does not improve immediately, and pain relief is maintained after many days. This prospective study aimed to evaluate the feasibility of quick opioid introduction with injectable oxycodone for outpatient cancer-related pain and bridge to oral persistent-release tablet. Patients with Numerical Rating Scale of ≥4 for cancer-related pain were included. Injectable oxycodone 2 mg was evaluated for efficacy and safety after 30 min of administration; in case of lower efficacy, injectable oxycodone was administered for another 30 min. For patients exhibiting improvement 30 and 60 min after injectable oxycodone administration, oral persistent-release tablet 5 and 10 mg were initiated, respectively. If side effects are acceptable, oral persistent-release tablet twice daily was prescribed. The final evaluation for its efficacy and safety was conducted at revisit. Overall satisfaction (1-5 points, higher points are better) was evaluated. The study included 23 patients (26 symptoms). The Numerical Rating Scale was improved from 6.7 ± 1.9 to 2.5 ± 2.5 and 1.3 ± 1.3 at 30 min after injectable oxycodone and revisit, respectively. Five patients with six symptoms receiving 60 min of injectable oxycodone had Numerical Rating Scale of 3.7 ± 1.7 and 1.7 ± 1.2 at revisit. No patient had Grade 3 or higher side effect during injectable oxycodone and at revisit. The overall satisfaction was 4.4 ± 0.8. In conclusion, early injectable oxycodone introduction for opioid-naïve outpatients can be feasible and useful as a quick bridge to oral persistent-release tablet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.